These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23372765)

  • 1. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
    Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
    PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
    Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
    Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
    Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
    J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
    Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
    J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.
    Osher DJ; De Leeneer K; Michils G; Hamel N; Tomiak E; Poppe B; Leunen K; Legius E; Shuen A; Smith E; Arseneau J; Tonin P; Matthijs G; Claes K; Tischkowitz MD; Foulkes WD
    Br J Cancer; 2012 Apr; 106(8):1460-3. PubMed ID: 22415235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
    Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
    J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.
    Tazzite A; Jouhadi H; Nadifi S; Aretini P; Falaschi E; Collavoli A; Benider A; Caligo MA
    Gynecol Oncol; 2012 Jun; 125(3):687-92. PubMed ID: 22425665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
    Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
    Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
    Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
    BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
    Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
    J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.